

Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/091001
	Serial No.	10/542,238
	Applicant	Kathleen FRESON et al.
	Filing Date	July 15, 2005
	Group	1644
	IDS Filed	June 17, 2009

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
/MS/	2002/0182729	December 5, 2002	DiCicco-Bloom et al.
/MS/	5,486,472	January 23, 1996	Suzuki et al.
/MS/	6,242,563	June 5, 2001	Dong

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
/MS/	WO 00/05260	February 3, 2000	WIPO	
/MS/	WO 00/23096	April 27, 2000	WIPO	
/MS/	WO 01/23420	April 5, 2001	WIPO	
/MS/	WO 2004/062684	July 29, 2004	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/MS/	Ashur-Fabian et al., "Identification of VIP/PACAP Receptors on Rat Astrocytes Using Antisense Oligodeoxynucleotides," <i>J. Mol. Neurosci.</i> 9(3):211-222 (1997).
/MS/	Bibel and Barde, "Neurotrophins: Key Regulators of Cell Fate and Cell Shape in the Vertebrate Nervous System," <i>Genes Dev</i> 14(23):2919-2937 (2000).
/MS/	Busto et al., "Evidence for Multiple Rat VPAC ₁ Receptor States with Different Affinities for Agonists," <i>Cell Signal.</i> 11(9):691-696 (1999).
/MS/	Cox et al., "VIP Elevates Platelet Cyclic AMP (cAMP) Levels and Inhibits <i>In Vitro</i> Platelet Activation Induced by Platelet-Activating Factor (PAF)," <i>Peptides</i> 5(2):325-328 (1984).
/MS/	Dhanjal et al., "A Novel Role for PECAM-1 in Megakaryocytokinesis and Recovery of Platelet Counts in Thrombocytopenic Mice," <i>Blood</i> 109(10):4237-4244 (2007).

EXAMINER	/Michael Szperka/	DATE CONSIDERED	06/29/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

Sheet 2 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50304/091001 10/542,238 Kathleen FRESON et al. July 15, 2005 1644 June 17, 2009
--	--	---	--

/MS/	Freson et al., "VPAC1 Receptor-Mediated Regulation of Megakaryopoiesis," <i>Blood</i> (ASH Annual Meeting Abstracts) 104:Abstract 735 (2004).
/MS/	Freson et al., "The Pituitary Adenylate Cyclase-Activating Polypeptide Is a Physiological Inhibitor of Platelet Activation," <i>J. Clin. Invest.</i> 113(6):905-912 (2004).
/MS/	Freson et al., "PACAP and Its Receptor VPAC1 Regulate Megakaryocyte Maturation: Therapeutic Implications," <i>Blood</i> 111(4):1885-1893 (2008).
/MS/	Goetzl et al., "Specific Recognition of the Human Neuroendocrine Receptor for Vasoactive Intestinal Peptide by Anti-Peptide Antibodies," <i>Mol. Cell. Neurosci.</i> 5(2):145-152 (1994).
/MS/	Kobayashi et al., "Interleukin 11," <i>Leuk. Lymphoma</i> 15(1-2):45-49 (1994).
/MS/	Sherwood et al., "The Origin and Function of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)/Glucagon Superfamily," <i>Endocrine Reviews</i> 21(6):619-670 (2000).
/MS/	Shima et al., "Characterization of VIP- and Helodermin-Preferring Receptors on Rat Platelets," <i>Regulatory Peptides</i> 63(2-3):99-103 (1996).
/MS/	Takizawa et al., "Growth and Maturation of Megakaryocytes Is Regulated by Lnk/Sh2b3 Adaptor Protein Through Crosstalk Between Cytokine- and Integrin-Mediated Signals," <i>Exp. Hematol.</i> 36(7):897-906 (2008).
/MS/	Tams et al., "Creation of a Selective Antagonist and Agonist of the Rat VPAC ₁ Receptor Using a Combinatorial Approach with Vasoactive Intestinal Peptide 6-23 as Template," <i>Mol. Pharmacol.</i> 58(5):1035-1041 (2000).

EXAMINER /Michael Szperka/	DATE CONSIDERED 06/29/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	